Evidence map›Paper›PMID 34518480›Full record

ArticleIntervirology2022

Prevalence of Hepatitis B Virus Infection Markers among Patients of the Ibn Sina University Hospital Center (Rabat, Morocco).

Mourad Feindiri, Hakima Kabbaj, Mohammed El Mzibri, Bouchra Belkadi, Najat Bouihat, Abdelkarim Filali-Maltouf, Myriam Seffar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Intervirology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mourad FeindiriCentral Laboratory of Virology, Ibn Sina University Hospital Center/Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco.
Hakima KabbajCentral Laboratory of Virology, Ibn Sina University Hospital Center/Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco.
Mohammed El MzibriMedical and Biological Research Unit, The National Center for Energy and Nuclear Science and Technology, Rabat, Morocco, mzibri@yahoo.com.
Bouchra BelkadiLaboratory of Microbiology and Molecular Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco.
Najat BouihatCentral Laboratory of Virology, Ibn Sina University Hospital Center/Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco.
Abdelkarim Filali-MaltoufLaboratory of Microbiology and Molecular Biology, Faculty of Sciences, Mohammed V University, Rabat, Morocco.
Myriam SeffarCentral Laboratory of Virology, Ibn Sina University Hospital Center/Faculty of Medicine and Pharmacy of Rabat, Mohammed V University, Rabat, Morocco.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionViral hepatitis B is a global scourge affecting millions of people worldwide. In Morocco, hepatitis B is considered a public health problem, and available data converge to consider Morocco as a country with intermediate endemicity. In the present study, we have planned to evaluate the HBV prevalence in Morocco on a large scale and to assess the prevalence of different serological markers for better management of this infection in Morocco.

methodsThis study was conducted on 18,877 patients referring to the Ibn Sina University Hospital Center of Rabat, Morocco. HBV serological markers including HBsAg, HBsAb, HBeAg, HBeAb, and total HBcAb were assessed by immune-enzymatic assays. The quantification of HBV DNA was performed by real-time PCR.

resultsThe overall prevalence of positive cases for HBsAg, HBsAb, and total HBcAb was 2.47%, 27.66%, and 21.2%, respectively. From 141 patients with an isolated HBcAb serological profile (HBcAb+/HBsAb-/HBsAg-), HBV DNA was detected in 10 patients, representing a rate of 7.09%. In the present study, up to 95.78% of HBV chronic carriers were negative for HBeAg.

conclusionThis study highlights a higher prevalence of HBsAg in the hospital-based population than the general population reported previously in Morocco and a very low HBV immunization coverage. Of particular interest, detectable HBV DNA levels in isolated HBcAb patients show that exclusive HBsAg screening cannot eliminate the risk of HBV transmission in certain cases. Many efforts are then mandatory to promote serological testing and increase the vaccination rate to limit viral dissemination for better management of this disease in Morocco.

Indexed as

Hepatitis BHepatitis B virusHepatitis B AntibodiesHepatitis B Surface AntigensHospitals, UniversityHumansMoroccoPrevalenceHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B virusMoroccoPrevalenceSerological markers

Identifiers

PMID34518480
PMCPMC9153348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.